Clinical Trial

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 15, 2024 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-21; most recent amendment 2024-11-13.
Trial Details
NCT Number NCT05673902
Lead Sponsor R-Pharm International, LLC
Collaborators: R-Pharm, Unimed Laboratories, Data Management 365, Exacte Labs LLC
Conditions Idiopathic Recurrent Pericarditis
Enrollment 17 participants
Start Date 2020-12-11
Primary Completion 2026-01 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-15